Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Allogene Takes Step Closer To Off-The-Shelf CAR-Ts

Executive Summary

Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion. 

You may also be interested in...



Allogene CAR-Ts’ Durability Remains A Question, But Strong Data So Far

Complete response rates for ALLO-501 and ALLO-501A look comparable so far to Gilead’s Yescarta, though longer follow-up is needed to judge if durability matches as well.

ASH 2020: Novel CAR-T Approaches Chase BCMA-Targeting Frontrunners

BMS/bluebird and Janssen/Legend have the leading BCMA-targeting CAR-T therapies for multiple myeloma but Poseida, Allogene, CARsgen, Gracell and CBMG are emerging with novel approaches. 

'We Jumped' At Opportunity To Take On Pfizer's CAR-T Program, Allogene's Chang Says

Former Kite exec David Chang is keen to use smaller firm's focus to advance allogeneic therapy more rapidly. The start-up acquired Pfizer R&D team along with its allogeneic CAR-T programs and related IP.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel